Retatrutide 20mg One*Pen
€189.99
€148.99Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Supplied as a Tera® One*Pen prefilled research device (2 × 10mg). Each unit includes 8 sterile needles and a research handling guide. For laboratory research use only.
After submitting, WhatsApp will open with your order pre-filled. We will confirm and send payment details.
Retatrutide
Retatrutide is an experimental peptide investigated in scientific studies as a triple agonist of GLP-1, GIP and glucagon receptors. Research focuses on mechanisms surrounding body weight, energy balance and metabolic regulation. Retatrutide is not approved by pharmaceutical authorities and is intended solely for research purposes.
This is a research-grade product for professionals: laboratory research such as in vitro studies, analytical testing and method development.
Scientific Background
In the literature, Retatrutide is investigated due to the simultaneous activation of three hormonal receptors involved in glucose metabolism, appetite regulation and energy expenditure. Through this combined receptor interaction, it offers researchers a model for analysing synergistic effects within metabolic signalling pathways.
Research focuses on factors such as the influence on energy balance, fat and glucose metabolism, and hormonal feedback mechanisms. The practical application of these findings outside controlled studies lacks scientific foundation.
Potential Research Areas and Effects
Within controlled research designs, Retatrutide has been studied in the following areas. This refers to research observations and does not constitute claims:
Weight and energy balance
Analysis of changes in energy intake and expenditure in experimental models.
Metabolic regulation
Research on glucose and fat metabolism and hormonal feedback loops.
Receptor interactions
Study of the combined activation of GLP-1, GIP and glucagon receptors.
Endocrine signalling pathways
Insight into how multiple hormonal axes are simultaneously affected.
Observed effects depend heavily on the study design, model and context and say nothing about safety or suitability for use outside the laboratory.
Safety and Research Context
Retatrutide falls outside regulated pharmaceutical applications and is not intended for clinical or veterinary use. The product is intended exclusively for professional researchers and R&D environments.
For research purposes only (e.g. in vitro, reference standard, assay development)
Use in accordance with internal laboratory protocols
Keep out of reach of unauthorised persons
Use outside controlled research environments carries greater and unpredictable risks
Frequently Asked Questions about Retatrutide
What is Retatrutide?+
Retatrutide is an experimental peptide used in research to study the combined activation of GLP-1, GIP and glucagon receptors.
What is Retatrutide researched for?+
It is studied in relation to weight, energy balance, glucose metabolism and metabolic signalling pathways.
Is Retatrutide approved?+
No. Retatrutide is not approved as a medicine and is intended solely for research purposes.
How does Retatrutide differ from other incretin-related peptides?+
It is distinguished by the simultaneous activation of three hormonal receptors, making it suitable for synergy research.
For what type of research is Retatrutide suitable?+
It is suitable for basic and applied research in metabolism, endocrinology and biomedical sciences.
Customer Reviews
Kelsea B.
Order APEX20260220-0269
I feel fuller for longer after eating.
06/03/2026
Callum
Order APEX20260219-0240
Retatrutide helps reduce overeating without feeling forced.
06/03/2026
Sandy R.
Order APEX20260307-1013
I noticed my cravings for sugary stuff went down quite a bit.
10/03/2026
Martin R.
Order APEX20260308-1075
What I like is that the appetite suppression feels natural, not extreme.
10/03/2026
Related Products
Retatrutide 10mg One*Pen
Triple GLP-1/GIP/Glucagon agonist. 4 × 2.5mg prefilled pen. For research use only.
Retatrutide 40mg One*Pen
Triple GLP-1/GIP/Glucagon agonist. 4 × 10mg prefilled pen. For research use only.
Tesamorelin(5mg / 10mg)
GHRH analogue for visceral fat reduction and growth hormone research.
AOD-9204
Growth hormone fragment for fat metabolism and weight management research.